Related Experiment Videos
Allogeneic bone marrow transplantation in multiple myeloma.
1Department of Hematology, Karolinska Institute, Huddinge University Hospital, Sweden.
Pathologie-Biologie
|April 8, 1999
Summary
Allogeneic transplantation offers a 50% complete remission rate for multiple myeloma, but faces high transplant-related mortality. Long-term survival is comparable to autologous transplants, with donor lymphocyte infusions showing promise for managing relapses.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Allogeneic transplantation can induce complete remission in multiple myeloma patients.
- Prognostic factors for survival include patient demographics, disease stage, prior treatment, and specific biomarkers.
Purpose of the Study:
- To evaluate the efficacy and outcomes of allogeneic transplantation in multiple myeloma.
- To identify prognostic factors influencing survival and transplant-related mortality.
- To explore strategies for improving outcomes and reducing relapse rates.
Main Methods:
- Analysis of complete remission rates, survival data, and transplant-related mortality in multiple myeloma patients undergoing allogeneic transplantation.
- Identification of prognostic factors such as sex, disease stage, treatment history, disease responsiveness, and beta-2 microglobulin levels.
- Review of strategies to mitigate transplant-related mortality and relapse, including stem cell selection and supportive therapies.
Main Results:
- Complete remission achieved in approximately 50% of patients.
- Five-year survival rates around 30%, with significant prognostic factors identified.
- Transplant-related mortality ranges from 40-50%, leading to poorer overall survival than autologous transplantation initially.
- Relapse rate in complete remission is approximately 50% at 5 years, lower than autologous transplantation.
- Donor lymphocyte infusions can induce remission in relapsed or persistent disease.
Conclusions:
- Allogeneic transplantation is a viable treatment for multiple myeloma, achieving significant remission rates.
- Strategies to reduce transplant-related mortality (e.g., stem cell selection, aggressive supportive care) and relapse (e.g., donor lymphocyte infusions, interferon) are crucial for improving patient outcomes.
- While initial overall survival may be lower than autologous transplantation due to mortality, long-term survival is comparable, and relapse rates are lower.